HB2198

HB2198 is a trispecific antibody-based therapeutic developed by Hinge Bio, designed to achieve rapid and deep B cell depletion in both peripheral blood and lymphoid tissues. Its mechanism of action involves cooperative binding to CD19, CD20, and Fc gamma receptors (FcγR), enabling potent engagement of immune effector cells such as natural killer (NK) cells and monocytes. The drug leverages Hinge Bio’s proprietary GEM-DIMER platform, which creates multivalent, multispecific antibodies with enhanced biological activity compared to conventional monoclonal antibodies or CAR-T therapies. HB2198 aims for an “immune reset” in patients with autoimmune diseases by providing profound B cell depletion while maintaining the safety profile of off-the-shelf antibody therapeutics. Preclinical data suggest superior efficacy over existing antibody-based therapies for B cell-mediated diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis, B-cell lymphoma, and other B-cell malignancies[1][2][3][5][6][8].

Other names

Tetravalent bispecific anti-CD19/CD20 antibodyAnti-CD19/CD20 bispecific antibody